Search for the Impact of Chemotherapy on the Immune Profile in Urothelial Carcinoma

Group Sylvie Rottey

Project 5

Description

Standard-of-care treatment of patients with urothelial carcinoma consists of platinum-containing chemotherapy followed by anti-PD1/PD-L1 immunotherapy upon progression to chemotherapy. In this research project, the immune profile in patients with muscle-invasive bladder cancer will be retrospectively determined before and after administration of neo-adjuvant chemotherapy. This will allow us to assess the impact of chemotherapy on the immune profile in urothelial carcinoma. Moreover, we will search for the possible use of combination therapies and efficiency of various neo-adjuvant strategies in bladder cancer. Lastly, we will examine the influence of radiotherapy on tolerance of and response to immunotherapy.

Funding Ageny

Unrestricted grant from Roche (2018)

Contact

Sylvie Rottey; MD, PhD (Medical Oncology – Ghent University Hospital)
Daan De Maeseneer; MD (Medical Oncology – Ghent University Hospital)
Stijn De Keukeleire; MD (Medical Oncology – Ghent University Hospital)
Tijl Vermassen; PhD (Medical Oncology – Ghent University Hospital)